Windlas Biotech Limited
NSE:WINDLAS.NS
859.85 (INR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,751.53 | 1,712.85 | 1,622.13 | 1,526.72 | 1,447.86 | 1,407.13 | 1,197.04 | 1,327.3 | 1,199.36 | 1,195.74 | 1,175.91 | 1,152.52 | 1,109.56 | 1,059.19 | 1,171.95 | 1,013.21 | 1,022.77 | 739.84 |
| Cost of Revenue
| 1,434.65 | 1,335.39 | 1,016.43 | 958.75 | 915.03 | 888.75 | 757.25 | 844.09 | 764.38 | 794.67 | 769.67 | 750.7 | 713.12 | 710.53 | 731.11 | 641.73 | 660.67 | 487.46 |
| Gross Profit
| 316.88 | 377.46 | 605.7 | 567.97 | 532.83 | 518.38 | 439.79 | 483.21 | 434.98 | 401.07 | 406.24 | 401.82 | 396.44 | 348.66 | 440.84 | 371.48 | 362.1 | 252.38 |
| Gross Profit Ratio
| 0.181 | 0.22 | 0.373 | 0.372 | 0.368 | 0.368 | 0.367 | 0.364 | 0.363 | 0.335 | 0.345 | 0.349 | 0.357 | 0.329 | 0.376 | 0.367 | 0.354 | 0.341 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 89.48 | 0 | 0 | 0 | 65.11 | 0 | 0 | 0 | 11.12 | 0 | 0 | 0 | 10.01 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 141.93 | 0 | 0 | 0 | 170.26 | 0 | 0 | 0 | 29.89 | 0 | 0 | 0 | 114.14 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 29.75 | 0 | 0 | 0 | 18.4 | 0 | 0 | 0 | 2.26 | 0 | 0 | 0 | 1.7 |
| SG&A
| 170.18 | 192.77 | 175.02 | 167.95 | 205.62 | 171.68 | 122.91 | 145.34 | 166.1 | 188.66 | 156.6 | 149.99 | 110.98 | 32.15 | 146.04 | 139.82 | 131.94 | 115.84 |
| Other Expenses
| 41.33 | 44.4 | 31.64 | 32.4 | 26.24 | 23.34 | 21.62 | 26.11 | 28.58 | -36.24 | 17.93 | 12.19 | 6.89 | -21.03 | 9.88 | 6.21 | 0 | 0 |
| Operating Expenses
| 170.18 | 192.77 | 436.22 | 414.4 | 393.29 | 389.66 | 331.65 | 351.81 | 324.62 | 288.55 | 307.27 | 301.02 | 302.84 | 245.09 | 300.43 | 280.96 | 464.3 | 231.39 |
| Operating Income
| 146.7 | 184.69 | 201.12 | 185.97 | 139.54 | 152.06 | 129.76 | 157.51 | 110.36 | 109.39 | 98.97 | 100.8 | 100.49 | 102.78 | 150.28 | 96.73 | 108.78 | 49.91 |
| Operating Income Ratio
| 0.084 | 0.108 | 0.124 | 0.122 | 0.096 | 0.108 | 0.108 | 0.119 | 0.092 | 0.091 | 0.084 | 0.087 | 0.091 | 0.097 | 0.128 | 0.095 | 0.106 | 0.067 |
| Total Other Income Expenses Net
| 36.41 | 41.63 | -3.05 | -2.85 | 23.86 | -1.65 | -1.57 | -1.16 | 25.08 | 27.17 | 15.82 | 7.83 | -4.82 | -20.53 | -4.08 | -3.03 | -213.52 | -33.75 |
| Income Before Tax
| 183.11 | 226.32 | 198.07 | 183.12 | 163.4 | 150.41 | 128.19 | 156.35 | 135.44 | 136.56 | 114.79 | 108.63 | 95.67 | 82.25 | 146.2 | 93.7 | -104.74 | 16.16 |
| Income Before Tax Ratio
| 0.105 | 0.132 | 0.122 | 0.12 | 0.113 | 0.107 | 0.107 | 0.118 | 0.113 | 0.114 | 0.098 | 0.094 | 0.086 | 0.078 | 0.125 | 0.092 | -0.102 | 0.022 |
| Income Tax Expense
| 48.32 | 56.39 | 47.09 | 42.81 | 42.75 | 35.97 | 36.31 | 34.41 | 37.14 | -11.32 | 31.65 | 25.63 | 28.8 | 23.29 | 23.39 | -0.68 | 15.7 | 11.53 |
| Net Income
| 134.79 | 169.93 | 150.98 | 140.31 | 120.65 | 114.44 | 91.88 | 121.94 | 98 | 147.88 | 83.14 | 83 | 66.87 | 58.96 | 122.82 | 94.38 | -117.82 | 4.63 |
| Net Income Ratio
| 0.077 | 0.099 | 0.093 | 0.092 | 0.083 | 0.081 | 0.077 | 0.092 | 0.082 | 0.124 | 0.071 | 0.072 | 0.06 | 0.056 | 0.105 | 0.093 | -0.115 | 0.006 |
| EPS
| 6.47 | 8.17 | 7.26 | 6.75 | 5.79 | 5.37 | 4.23 | 5.6 | 4.5 | 6.97 | 3.81 | 4.11 | 3.67 | 3.24 | 6.75 | 5.18 | -6.47 | 0.25 |
| EPS Diluted
| 6.44 | 8.14 | 7.26 | 6.75 | 5.79 | 5.37 | 4.23 | 5.59 | 4.5 | 6.79 | 3.81 | 4.1 | 2.05 | 3.24 | 6.75 | 5.18 | -6.47 | 0.25 |
| EBITDA
| 208.8 | 220.05 | 235.01 | 219.27 | 197.67 | 187.74 | 161.11 | 186.56 | 166.5 | 168.46 | 148.35 | 143.74 | 130.74 | 136.36 | 183.68 | 129.55 | 129.673 | 67.16 |
| EBITDA Ratio
| 0.119 | 0.128 | 0.145 | 0.144 | 0.137 | 0.133 | 0.135 | 0.141 | 0.139 | 0.141 | 0.126 | 0.125 | 0.118 | 0.129 | 0.157 | 0.128 | 0.127 | 0.091 |